WebDec 13, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal... WebExplore {Cytokinetics's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Cytokinetics …
Third Rock biotech startups find work-share partner in Cytokinetics ...
WebJul 19, 2024 · Cytokinetics plans to advance its small molecule to Phase 3 testing by the end of this year. A Cytokinetics drug candidate in development to treat the same rare heart condition as a Bristol Myers ... Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998. Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. … See more Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases … See more Omecamtiv mecarbil, a cardiac muscle activator for the potential treatment of heart failure. In May 2024, omecamtiv mecarbil was granted fast track designation by the FDA for … See more Official website See more eap all one health
Ronald Vale - executive @ Cytokinetics - Person Profile - Cointime
WebOct 14, 2024 · Authors. Chihyuan Chuang 1 , Scott Collibee 1 , Luke Ashcraft 1 , Wenyue Wang 1 , Mark Vander Wal 1 , Xiaolin Wang 1 , Darren T Hwee 1 , … WebCytokinetics, Inc. Confidential 2 ACS National Meeting Spring 2024 04.09.21 Heart Failure: Many Phenotypes with Unmet Need. Inability to pump an adequate supply of blood to the body. Increased / Preserved Cardiac Contractility. Non-obstructive Hypertrophic Cardiomyopathy (nHCM) WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media … eapa national website